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A
 
BSTRACT
 
Background
 
It is uncertain whether treatment of
 
Helicobacter pylori
 
 infection relieves symptoms in
patients with nonulcer, or functional, dyspepsia.
 
Methods
 
We conducted a double-blind, multicenter
trial of patients with 
 
H. pylori
 
 infection and dyspeptic
symptoms (moderate-to-very-severe pain and dis-
comfort centered in the upper abdomen). Patients
were excluded if they had a history of peptic ulcer
disease or gastroesophageal reflux disease and had
abnormal findings on upper endoscopy. Patients
were randomly assigned to seven days of treatment
with 20 mg of omeprazole twice daily, 1000 mg of
amoxicillin twice daily, and 500 mg of clarithromycin
twice daily or with omeprazole alone and then fol-
lowed up for one year. Treatment success was de-
fined as the absence of dyspeptic symptoms or the
presence of minimal symptoms on any of the 7 days
preceding the 12-month visit.
 
Results
 
Twenty of the 348 patients were excluded
after randomization because they were not infected
with 
 
H. pylori,
 
 were not treated, or had no data avail-
able. For the remaining 328 patients (164 in each
group), treatment was successful for 27.4 percent of
those assigned to receive omeprazole and antibiotics
and 20.7 percent of those assigned to receive omep-
razole alone (P=0.17; absolute difference between
groups, 6.7 percent; 95 percent confidence interval,
¡2.6 to 16.0). After 12 months, gastritis had healed
in 75.0 percent of the patients in the group given
omeprazole and antibiotics and in 3.0 percent of the
patients in the omeprazole group (P<0.001); the re-
spective rates of 
 
H. pylori
 
 eradication were 79 percent
and 2 percent. In the group given omeprazole and
antibiotics, the rate of treatment success among pa-
tients with persistent 
 
H. pylori
 
 infection was similar
to that among patients in whom the infection was
eradicated (26 percent vs. 31 percent). There were no
significant differences between the groups in the
quality of life after treatment.
 
Conclusions
 
In patients with nonulcer dyspepsia,
the eradication of 
 
H. pylori
 
 infection is not likely to
relieve symptoms. (N Engl J Med 1998;339:1875-81.)
 
©1998, Massachusetts Medical Society.
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PPROXIMATELY one third of people in
industrialized nations have recurrent dys-
peptic symptoms, or dyspepsia, many of
whom have no evidence of chronic peptic
ulceration, reflux esophagitis, a malignant condition,
or other defined organic disease.
 
1-4
 
 The ambiguity in
the diagnosis has led to the development of various
definitions of dyspepsia, dyspeptic symptoms, and
nonulcer, or functional, dyspepsia, based on available
clinical, epidemiologic, and pathophysiologic data.
 
5
 
Nonulcer dyspepsia is defined as “persistent or re-
current abdominal pain or discomfort centered in the
upper abdomen in patients who have no definite struc-
tural or biochemical explanation for their symptoms
(e.g., peptic ulcer disease, gastroesophageal reflux
disease, malignancy or pancreaticobiliary disease).”
 
6
 
The pathogenesis of nonulcer dyspepsia is unknown,
but disturbances of visceral perception, gastric acid
secretion, and gastroduodenal motility, as well as
 
H. pylori
 
 infection, have been implicated.
 
7
 
 The re-
ported prevalence of 
 
H. pylori
 
 infection in patients
with gastritis and nonulcer dyspepsia ranges from 30
to 70 percent.
 
3,8
 
 As yet, however, it is uncertain
whether 
 
H. pylori
 
 infection causes the dyspeptic symp-
toms in these patients.
We compared the effect of one week of treatment
with omeprazole, amoxicillin, and clarithromycin with
that of one week of treatment with omeprazole alone
on the relief of symptoms, eradication of 
 
H. pylori
 
infection, healing of gastritis, and quality of life in
patients with nonulcer dyspepsia. Given the evidence
that regression of 
 
H. pylori
 
–induced gastritis could
take at least 1 year after the successful cure of the in-
fection,
 
9
 
 we followed the patients for 12 months.
A
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METHODS
 
Study Design
 
This randomized, double-blind study was conducted in numer-
ous centers in Austria, Canada, Germany, Iceland, Ireland, South
Africa, and Sweden between December 1995 and December
1997, according to the principles of good clinical practice and in
accordance with the revised Declaration of Helsinki. The study
protocol and patient information and consent form were approved
by an independent ethics committee at each study center, and
written informed consent was obtained from the patients before
enrollment.
 
Selection of Patients
 
Patients who sought medical care for dyspeptic symptoms (spe-
cifically, pain or discomfort centered in the upper abdomen) that
had been present for at least six months and who had no history
of peptic ulcer disease or gastroesophageal disease were eligible
for the study, provided they had normal endoscopic findings (i.e.,
five or fewer gastric erosions and no esophageal, gastric, or duo-
denal ulcers, esophageal or duodenal erosions, or Barrett’s esoph-
agus) and were 
 
H. pylori
 
–positive on analysis with the rapid urease
test (HUT, Astra, Wedel, Germany). After enrollment, blood
samples were obtained for routine laboratory screening, to check
for any chemical or hematologic abnormalities. Patients were given
diary cards and asked to evaluate their dyspeptic symptoms at bed-
time each evening for a run-in period of seven days, during which
they received no treatment. The symptoms were graded with use
of a validated seven-point Likert
 
10
 
 scale as absent (score of 0), min-
imal (1), mild (2), moderate (3), moderately severe (4), severe
(5), or very severe (6). Only patients with moderate-to-very-severe
pain or discomfort centered in the upper abdomen on at least
three days during the run-in period underwent randomization in
blocks of two, according to a computer-generated list. Patients with
unintentional weight loss, dysphagia, hematemesis, or any other
signs indicating serious disease were excluded. Treatment with
histamine H
 
2
 
-receptor antagonists, prostaglandins, or prokinetic
agents during the seven days before entry into the study was not
permitted, nor was treatment with proton-pump inhibitors, anti-
biotics, or bismuth-containing compounds during the month be-
fore the study began.
 
Study Protocol
 
At the end of the one-week run-in period, patients who ful-
filled the selection criteria were randomly assigned to one week of
treatment with either 20 mg of omeprazole (Losec, Astra, Söd-
ertälje, Sweden) twice daily (morning and evening), 1000 mg of
amoxicillin (Amimox, Astra) twice daily, and 500 mg of clarith-
romycin (Bremón, Abbott Laboratories, Madrid, Spain) twice daily
or 20 mg of omeprazole twice daily, as well as placebo antibiotics.
The treatments were given orally in a double-blind fashion, and ac-
tive and placebo tablets were identical in appearance. The patients
returned to the clinic after 1 week and 1, 3, 6, 9, and 12 months
after the end of treatment.
 
Endoscopy, Biopsy, and the Urea Breath Test
 
Endoscopy and biopsy were performed before the run-in period
and 3 and 12 months after treatment was completed. Two biopsy
specimens of the antrum, corpus, and angulus were obtained for
histologic analysis at each visit, and one additional specimen of
the antrum and the corpus was obtained during the preliminary
endoscopy for the rapid urease test. The patients also underwent a
urea breath test
 
11
 
 at the end of the run-in period and again 3 and
12 months after treatment to confirm their 
 
H. pylori
 
 status. Pa-
tients were regarded as positive for 
 
H. pylori
 
 at randomization if
they had a positive rapid urease test and a positive urea breath test
or abnormal histologic findings (or both). At the 3-month and
12-month follow-up visits, patients were regarded as positive for
 
H. pylori
 
 if they had a positive urea breath test, abnormal histo-
logic findings, or both. In the case of patients who did not take
these tests or whose data were lost, the 
 
H. pylori
 
 status was de-
fined as unknown. Neither the patients nor the investigators were
aware of the patients’ 
 
H. pylori
 
 status during the study.
 
Histologic Analysis
 
The biopsy specimens were embedded in paraffin and cut into
4-µm sections perpendicularly to the mucosal surface. They were
then stained with hematoxylin and eosin and Warthin–Starry silver,
and the severity of gastritis was graded according to the Houston
modification of the Sydney system.
 
12
 
Assessment of the Quality of Life
 
We assessed the patients’ quality of life on four occasions during
the study — at randomization, after the completion of treatment,
and at the 6-month and 12-month follow-up visits — with the
use of two validated questionnaires. The Gastrointestinal Symptom
Rating Scale assesses the severity of indigestion, diarrhea, constipa-
tion, abdominal pain, and reflux, and scores can range from 1 (no
symptoms) to 7 (severe symptoms).
 
13
 
 The Psychological General
Well-Being Index
 
14
 
 measures subjective well-being in terms of anxi-
ety, depressed mood, positive well-being, self-control, and general
health and vitality. The worst possible score is 22, and the best pos-
sible is 132. We also assessed the overall effect of treatment 6 and
12 months after it had ended by comparing the severity of dys-
peptic symptoms before and after treatment with a Likert scale in
which a score of ¡6 indicated that symptoms were “a great deal
worse,” a score of 0 that symptoms were “about the same,” and
a score of 6 that symptoms were “a very great deal better.”
 
Statistical Analysis
 
The sample size was calculated to allow two primary comparisons
between the groups: the relief of dyspeptic symptoms and healing
of gastritis. The significance level was adjusted to 2.5 percent for
each comparison with the Bonferroni correction.
 
15
 
 The assumed
rate of treatment success was 40 percent in the group assigned to
receive omeprazole and antibiotics and 20 percent in the group
assigned to receive omeprazole alone. With the use of a two-sided
test and a power of 80 percent for the comparison of dyspeptic
symptoms, the study required a total of 320 patients (160 patients
in each group), up to 25 percent of whom could be deemed un-
able to be evaluated. With a sample of this size, the power of the
study to detect differences in the rates of healing of gastritis was
about 95 percent. The healing rates were assumed to be 50 percent
in the group assigned to receive omeprazole and antibiotics and
20 percent in the group assigned to receive omeprazole alone.
The intention-to-treat analyses included all patients who received
at least one dose of medication and who were 
 
H. pylori
 
–positive
at entry. In the analyses per protocol, all patients with major de-
viations from the protocol (use of prohibited drugs before study
entry, insufficiently severe symptoms during the run-in period,
abnormal findings on pre-entry endoscopy, and history of peptic
ulcer disease) were excluded. For the predetermined primary eval-
uation, treatment was considered successful if a patient reported
no symptoms or no more than minimal pain or discomfort centered
in the upper abdomen during any of the 7 days preceding the 12-
month visit (a score of 0 or 1) on the daily diary cards. The other
main response variable was healing of gastritis. Treatment success
and healing of gastritis were compared between groups with a
Mantel–Haenszel test
 
16
 
 stratified according to country. The ef-
fects of the countries were assessed with the Breslow–Day test.
 
16
 
The proportion of patients in whom 
 
H. pylori
 
 infection was erad-
icated was estimated, and values are given with 95 percent confi-
dence intervals. The quality-of-life scores were compared between
the two groups with the use of analysis of variance, with base-line
scores included as a covariate.
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RESULTS
 
Patient Population
 
We screened 466 patients and excluded 118. Of
the 348 patients who were randomly assigned to a
treatment group, 328 were included in the intention-
to-treat analysis and 245 were included in the per-
protocol analysis (Fig. 1). The reasons for exclusion
from the analyses are given in Figure 1. The base-
line characteristics of the two treatment groups were
similar (Table 1).
 
Treatment Success and Healing of Gastritis
 
The rates of treatment success and healing of gas-
tritis are given in Table 2. The rates of treatment suc-
cess were similar in the group given omeprazole,
amoxicillin, and clarithromycin and the group given
omeprazole alone whether they were analyzed accord-
ing to the intention to treat (27.4 percent vs. 20.7
percent; absolute difference between groups, 6.7 per-
cent; 95 percent confidence interval, ¡2.6 to 16.0)
or per protocol (28.2 percent vs. 24.0 percent; abso-
lute difference between groups, 4.3 percent; 95 per-
cent confidence interval, ¡6.8 to 15.3). A Breslow–
Day test showed no indication of any inhomogeneity
in the results according to the country in which pa-
tients were treated (P>0.7) in either analysis.
The proportions of patients with no symptoms or
minimal symptoms (as recorded on the diary cards)
 
Figure 1.
 
 Numbers of Patients Enrolled in the Study and Analyzed According to the Intention to Treat or per Protocol.
466 Screened
348 EnrolledN
Omeprazole andN
antibiotics (n=172)N
Omeprazole aloneN
(n=176)N
N
40 ExcludedN
Major deviation fromN
inclusion criteria (n=12)N
Discontinuation due toN
adverse event (n=9)N
Loss to follow-up orN
refusal to continue (n=12)N
Eradication therapy duringN
follow-up (n=1)N
Noncompliance (n=3)N
Other (n=3)
43 ExcludedN
Major deviation fromN
inclusion criteria (n=10)N
Discontinuation due toN
adverse event (n=2)N
Loss to follow-up orN
refusal to continue (n=15)N
Eradication therapy duringN
follow-up (n=1)N
Noncompliance (n=2)N
Other (n=13)
124 Included in per-N
protocol analysis 
20 ExcludedN
Not treated orN
no data (n=3)N
Helicobacter pylori–N
negative (n=17)
118 ExcludedN
Inclusion criteriaN
not fulfilled (n=97)N
Patient declined (n=17)N
Other (n=4)
121 Included in per-N
protocol analysis 
164 in omeprazole-and-N
antibiotics group includedN
in intention-to-treat analysis
164 in omeprazole-aloneN
group included inN
intention-to-treat analysis
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during the 7 days before each visit at 6, 9, or 12
months were not significantly different between the
two groups whether the data for each time point were
analyzed separately or together (13 percent in the
group given omeprazole and antibiotics and 10 per-
cent in the group given omeprazole alone; P=0.61
by two-sided Fisher’s exact test). Similarly, when the
mean symptom scores (Fig. 2) for the visits at 6, 9,
and 12 months were compared, there was no signifi-
cant difference between groups (1.73 in the group
given omeprazole and antibiotics and 1.74 in the
group given omeprazole alone; P=0.9). 
The proportion of patients without gastritis at 12
months was significantly higher in the group given
omeprazole and antibiotics than in the group given
omeprazole alone (75.0 percent vs. 3.0 percent;
P<0.001, according to the intention-to-treat analysis)
(Table 2). The results were similar when the data
were analyzed per protocol (Table 2).
 
Quality of Life
 
In both groups, the patients’ quality of life im-
proved after treatment, but not significantly. Overall,
the mean scores for the Psychological General Well-
Being Index (Fig. 3) and the Gastrointestinal Symp-
tom Rating Scale (data not shown) improved, but
there were no significant differences between groups
whether the data were analyzed separately for each
portion of the scale or for the total score. With re-
spect to the overall effect of treatment, two thirds of
the patients in each group reported an improvement
in symptoms; the other third indicated that they felt
about the same as they had at entry.
 
Eradication of 
 
H. pylori
 
 Infection
 
According to the intention-to-treat analysis, 
 
H. py-
lori
 
 infection was eradicated in 79 percent (95 per-
cent confidence interval, 72 to 85 percent) of the
patients in the group given omeprazole and antibiot-
ics (because of missing data, the outcome was un-
known for 9 percent) and 2 percent (95 percent con-
fidence interval, 1 to 7 percent) of the patients in the
group given omeprazole alone (the outcome was
unknown for 10 percent). In the group given omep-
razole and antibiotics, 31 percent of those who were
cured had relief of symptoms, as compared with 26
percent of those who remained 
 
H. pylori
 
–positive.
According to the analysis per protocol, which ex-
cluded patients for whom the outcome was unknown,
 
H. pylori
 
 infection was eradicated in 87 percent of
the patients (108 of 124) in the group given omep-
razole and antibiotics.
 
*Subjects were asked whether they smoked daily.
 
T
 
ABLE
 
 1. 
 
B
 
ASE
 
-L
 
INE
 
 C
 
HARACTERISTICS
 
 
 
OF
 
 
 
THE
 
 328 P
 
ATIENTS
 
 I
 
NCLUDED
 
 IN THE
INTENTION-TO-TREAT ANALYSIS.
CHARACTERISTIC
OMEPRAZOLE
AND ANTIBIOTICS
(N=164)
OMEPRAZOLE 
ALONE
(N=164)
Age (yr)
Mean 
Range
47
18–79
47
19–76
Sex (M/F) 65/99 71/93
Mean weight (kg)
Men
Women
78
66
76
68
White race (%) 87 88
Smoking status (%)*
Current smoker
Former smoker
30
21
27
18
Daily alcohol use (%) 46 42
Duration of dyspepsia >1 yr (%) 79 84
*CI denotes confidence interval.
†Data on biopsy assessments were missing for 36 patients, 16 in the group given omeprazole and
antibiotics and 20 in the group given omeprazole alone.
TABLE 2. RATES OF SUCCESSFUL TREATMENT AND HEALING OF GASTRITIS,
ACCORDING TO THE INTENTION-TO-TREAT ANALYSIS AND ANALYSIS PER PROTOCOL.
VARIABLE
OMEPRAZOLE
AND ANTIBIOTICS
OMEPRAZOLE
ALONE
ABSOLUTE DIFFERENCE
BETWEEN GROUPS
(95% CI)*
P 
VALUE
% (no. of patients/total no.) %
Intention-to-treat analysis
Treatment success 27.4 (45/164) 20.7 (34/164) 6.7 (¡2.6 to 16.0) 0.17
Healing of gastritis† 75.0 (123/164) 3.0 (5/164) 72.0 (64.8 to 79.1) <0.001
Per-protocol analysis
Treatment success 28.2 (35/124) 24.0 (29/121) 4.3 (¡6.8 to 15.3) 0.45
Healing of gastritis 82.0 (100/122) 3.4 (4/117) 78.5 (70.8 to 86.3) <0.001
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Relation among Healing of Gastritis, Eradication 
of Infection, and Treatment Success
In the group given omeprazole and antibiotics,
119 of the patients had healing of gastritis and erad-
ication of H. pylori infection. The rate of treatment
success in this subgroup was 30 percent, as com-
pared with a rate of 29 percent among the 14 pa-
tients in whom gastritis did not resolve and H. pylori
was not eradicated. The remaining 31 patients in
this group had either healing of gastritis or eradica-
tion of H. pylori infection, but not both, or had data
missing. In the group given omeprazole alone, 137
of the patients remained positive for H. pylori and
had unhealed gastritis. The rate of treatment success
in this subgroup was 23 percent, as compared with
a rate of 0 percent among the three patients with
resolution of gastritis and eradication of infection.
The remaining 24 patients in this group had either
healing of gastritis or eradication of H. pylori infec-
tion, but not both, or had data missing.
At the 12-month follow-up visits, 11 patients in the
group given omeprazole and antibiotics had lesions
(10 had erosive esophagitis and 1 had a gastric ulcer),
as compared with 9 patients in the group given
omeprazole alone (3 had erosive esophagitis, 4 had
gastric ulcers, and 2 had duodenal ulcers).
Evaluation of Safety
Safety data were available for 169 patients in the
group given omeprazole and antibiotics and 176 pa-
tients in the group given omeprazole alone. There
were no serious adverse events in either group dur-
ing treatment. Few patients had treatment stopped
because of an adverse event: 12 in the group given
omeprazole and antibiotics and 2 in the group given
omeprazole alone. The most common adverse event,
diarrhea, occurred in 63 patients in the group given
omeprazole and antibiotics and in 10 patients in the
group given omeprazole alone.
DISCUSSION
Peptic ulcer disease is strongly associated with
H. pylori infection. The eradication of this infection
prevents relapse of gastric and duodenal ulcers, un-
less reinfection occurs or patients take ulcerogenic
drugs such as nonsteroidal antiinflammatory drugs.17,18
Figure 2. Mean Symptom Scores during the Seven-Day Run-in Period (Base Line) and during the Seven
Days before Each Follow-up Clinic Visit.
Patients were given diary cards and asked to evaluate their dyspeptic symptoms. A score of 0 indicates
the absence of symptoms, and a score of 6 the presence of very severe symptoms. Treatment success
was defined as a score of 0 or 1.
0
6
1
2
3
4
5
Omeprazole andN
antibioticsN
Mean (±SE) scoreN
No. of patientsN
Omeprazole aloneN
Mean (±SE) scoreN
No. of patients
N
N
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164N
N
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164
N
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N
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A role for H. pylori in nonulcer dyspepsia also seems
plausible, and numerous studies have investigated a
possible link. However, the results of clinical trials
have so far been equivocal, and the role of H. pylori
remains highly controversial.7,19,20 In a recent critique
of 16 therapeutic trials in patients with nonulcer
dyspepsia who had H. pylori infection,21 all of the
studies were considered to have at least one serious
methodologic weakness. Our study guidelines were
drawn up after a systematic review of trial methods.22
We used a strict definition of nonulcer dyspepsia,6
since this was one of the major variants in previous
studies. It can be argued that if the entry criteria are
too strict, the study group is not truly representative
of people with dyspepsia, but the use of more relaxed
criteria may result in the inclusion of patients with
other gastrointestinal diseases, such as gastroesoph-
ageal reflux disease and peptic ulcer disease. The in-
clusion of patients with gastroesophageal reflux dis-
ease may decrease the chance of a positive response,
whereas the inclusion of patients with peptic ulcer dis-
ease may increase the chance of a positive response.
We based our sample size on careful predictions
of efficacy and included a 12-month period of follow-
up, which is sufficient time to allow healing of gas-
tritis.9 H. pylori infection was detected with the use
of validated methods11,12 and treated optimally with
omeprazole, amoxicillin, and clarithromycin,23,24 and
both patients and physicians were unaware of the pa-
tients’ H. pylori status at follow-up. The rather low
rate of eradication of H. pylori infection in the inten-
tion-to-treat analysis of the group given omeprazole
and antibiotics was for the most part accounted for
by the relatively large proportion (9 percent) of pa-
tients for whom the outcome was unknown.
Studies of nonulcer dyspepsia have often been
criticized for failing to use validated outcome meas-
ures.22 We used a stringent definition of treatment
success: the absence of symptoms or the presence of
only minimal symptoms. As a means of determining
the response, we used a Likert scale to assess the se-
verity of symptoms25,26 as well as the Gastrointestinal
Symptom Rating Scale and the Psychological Gen-
eral Well-Being Index, both of which have been val-
idated and widely used in different countries,13,14,27-29
to assess the patients’ quality of life.
There were no significant differences in the rates
of symptom relief or other secondary variables be-
tween the two treatment groups during the 12 months
of follow-up, and there was also no apparent differ-
ence in the rates of treatment success between pa-
tients in whom gastritis had healed and H. pylori was
eradicated and those with persistent gastritis and in-
fection. Although the quality of life after treatment
Figure 3. Mean Scores for the Psychological General Well-Being Index at Base Line and after Treatment
with Omeprazole and Antibiotics or Omeprazole Alone.
The Psychological General Well-Being Index was used to assess the patients’ quality of life. On this
scale, the worst possible score is 22, and the best possible is 132.
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did not differ significantly between the two groups,
both groups had a marked improvement in all the
variables analyzed in this assessment, including the
severity of dyspeptic symptoms, as reported previ-
ously in many other studies.21,30,31 This finding con-
firms that we used sensitive instruments of assessment.
In studies of nonulcer dyspepsia, the use of repeat-
ed endoscopy is important to rule out the possibility
of a high incidence of ulcers at follow-up. In our study,
fewer than 3 percent of patients had peptic ulcers at
follow-up and all but one of the ulcers occurred in
patients with persistent H. pylori infection. These
results suggest that we did not include patients who
had peptic ulcer disease but had no evidence of it on
endoscopy and instead included only patients with
non-ulcer dyspepsia. We conclude that although the
eradication of H. pylori infection may help prevent
or cure peptic ulcer disease, it is not likely to have a
major role in the treatment of symptoms in patients
with nonulcer dyspepsia.
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APPENDIX
In addition to the authors, other members of the Omeprazole plus Cla-
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L.-H. Griem, U. Pannewick, B. Marowski, H.-J. Schulz, I. Ajer, N. Städler,
K. Gail, B. Albrecht, A. Velthof, M. Frömmel; Iceland — K. Örvar, S.
Kristjánsdóttir, Ó. Gunnlaugsson, B. ∏jó∂leifsson, H. Gu∂jónsson, A.
Bö∂varsson, S. Ólafsson; Ireland — M. Buckley, J. Lee, N. Breslin, C. Fal-
lon, C. Forkin, D. McNamara, S. Montague, D. Weir, B. Ryan, N. Mah-
mud, S. McKiernan, D. O’Toole, D. Kelleher, V. Pippet; South Africa —
T. Winter, A. Cariem, W. Osler, G. Smit, G. Adams, C. van Rensburg, A.
Thorpe, E. Wilken, A. Simjee, F. Makumbi, P. Soni; and Sweden — K.
Melén, B. Bergman, L. Carling, L. Svedberg, H. Törnblom, G. Engström,
P. Götell, H. Forsell, B. Ohlin, B. Hallerbäck, E. Johnsson, T. Hallgren,
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